ClinicalTrials.gg
TerminatedNCT02956629Updated Feb 2, 2021Results posted

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

A Phase 2 interventional study of Uprifosbuvir and Ruzasvir in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated based on review of Phase 2 efficacy data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hepatitis C by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C · Merck & Co., Inc.

Enrollment
10th of 69
282 · median 60
Started
2016
with 2 others
Phase 2
20 of 92
none open now
Registered
88th of 92
by date

Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 10th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 2, and was the 88th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 92 studies in Hepatitis C by Merck & Co., Inc is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 92 studies in Hepatitis C by Merck & Co., Inc as a file.
02

Study summary

This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir [MK-3682] 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.

Read the detailed description

Any GT that meets virologic futility criteria will be given the option of extending treatment with uprifosbuvir + RZR to 16 weeks with ribavirin (RBV) added.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has ribonucleic acid (RNA) (≥10,000 IU/mL in peripheral blood) at the time of screening
  • has documented chronic HCV GT1, GT2, GT3, GT4, GT5, or GT6 (with no evidence of non-typeable or mixed GT)
  • is a female who is not of , or is a female of reproductive potential who agrees to avoid becoming pregnant from two weeks prior to Day 1 through 14 days after the last dose of study drug via abstinence or use of two approved
  • is C or NC
  • if coinfected with , has documented HIV infection prior to Day 1, and either does not use an antiretroviral therapy (ART) or has well-controlled HIV on stable ART (at least 4 weeks prior to study entry)

Exclusion criteria

Exclusion Criteria:

  • has evidence of decompensated liver disease
  • is C and is Class B or C, or has a Child-Tucotte-Pugh score >6
  • is coinfected with virus (hepatitis B surface antigen or hepatitis B core antibody positive)
  • is coinfected with and has a recent (within 6 months prior to screening) opportunistic infection
  • has a history of other than adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ within 5 years of signing
  • is C and has evidence (liver imaging within 6 months prior to Day 1) of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • has participated in another drug study within 30 days of signing informed consent
  • is a female who is pregnant or breastfeeding or expecting to conceive or donate eggs from Day 1 through 6 months after the last dose of study drug or longer if dictated by local regulations, or is a male who is expecting to donate sperm from Day 1 through 14 days after the last dose of study drug or longer if dictated by local regulations, or is a male whose female partner(s) is/are pregnant or breastfeeding
  • has alcohol or drug abuse within 12 months of screening
  • has any of the following conditions: organ transplants other than cornea and hair; poor venous access; history of gastric surgery; clinically significant cardiac abnormality/dysfunction; any major medical condition which, in the opinion of the investigator, might interfere with participation; hospitalization within 3 months prior to enrollment; any condition that might require hospitalization; any condition requiring or likely to require chronic systemic administration of , tumor necrosis factor (TNF) antagonists, or drugs; a life-threatening SAE during screening; or hepatitis not caused by
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    HCV GT1

    Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

  • Experimental
    HCV GT2

    Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

  • Experimental
    HCV GT3

    Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

  • Experimental
    HCV GT4

    Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

  • Experimental
    HCV GT5

    Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

  • Experimental
    HCV GT6

    Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.

    Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin

Interventions

  • Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

    Also known as: MK-3682

  • Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

    Also known as: MK-8408

  • RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)

    Plasma levels of hepatitis C virus (HCV) ribonucleic acid (RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR12 is the absence of detectable RNA of the hepatitis C virus, (\<lower limit of quantification \[LLOQ\] of 15 IU/mL) for at least 12 weeks after completing treatment.

    Time frame: 12 weeks after completing study therapy (Week 24)

  2. Percentage of Participants Experiencing an Adverse Event (AE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to Week 14

  3. Percentage of Participants Experiencing an AE of Clinical Importance (ECI)

    Adverse events of clinical importance, excluding overdoses include, but is not limited to, significant changes in alanine aminotransferase, aspartate aminotransferase, blood creatinine, glomerular filtration rate or hepatitis B reactivation.

    Time frame: Up to Week 14

  4. Percentage of Participants Experiencing a Serious Adverse Event (SAE)

    A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose.

    Time frame: Up to Week 14

  5. Percentage of Participants Experiencing a Drug-related AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE is determined by the investigator to be related to the use of the drug.

    Time frame: Up to Week 14

  6. Percentage of Participants Experiencing a Drug-related SAE

    A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose. A drug-related SAE is determined by the investigator to be related to the use of the drug.

    Time frame: Up to Week 14

  7. Percentage of Participants Discontinuing Study Therapy Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to Week 12

Secondary outcomes

  1. Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)

    Plasma levels of HCV RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR24 is the absence of detectable RNA of the hepatitis C virus (\<LLOQ of 15 IU/mL), for at least 24 weeks after completing treatment.

    Time frame: 24 weeks after completing study therapy (Week 36)

  2. Percentage of Participants With Virologic Failure

    Virologic failure is the detection of HCV RNA among participants who do not discontinue study for non-treatment-related reasons, either due to on-treatment failure defined as either non-response where HCV RNA is detected at end of treatment without HCV RNA \<LLOQ having been achieved while on treatment; rebound defined as \>1 log10 IU/mL increase in HCV RNA from nadir while on treatment and confirmed from a separate blood draw within 2 weeks; or virologic breakthrough which is confirmed HCV RNA ≥LLOQ (target detected, quantifiable \[TD(q)\]) after being \<LLOQ previously while on treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks; or relapse post-treatment. where there is a confirmed HCV RNA ≥LLOQ \[TD(q)\] following end of all study therapy, after becoming undetectable (target not detected \[TND\]) at end of treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks.

    Time frame: Up to Week 24

07

Results

Posted Dec 26, 2018

Participant flow

Males and females of at least 18 years of age, with chronic Hepatitis C Virus (HCV) infection were enrolled in this study.

Participant flow — Overall Study
MilestoneHCV Genotype (GT) 1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Started784761561822
Completed734157551821
Not completed564101
Withdrew: Adverse event001000
Withdrew: Lost to follow-up253101
Withdrew: Withdrawal by subject310000

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)

Plasma levels of hepatitis C virus (HCV) ribonucleic acid (RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR12 is the absence of detectable RNA of the hepatitis C virus, (\<lower limit of quantification \[LLOQ\] of 15 IU/mL) for at least 12 weeks after completing treatment.

Time frame:
12 weeks after completing study therapy (Week 24)
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)92.3 (84.0 to 97.1)91.5 (79.6 to 97.6)73.8 (60.9 to 84.2)98.2 (90.4 to 100.0)100.0 (81.5 to 100.0)90.9 (70.8 to 98.9)
PrimaryPercentage of Participants Experiencing an Adverse Event (AE)

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing an Adverse Event (AE)
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Experiencing an Adverse Event (AE)60.361.757.455.477.877.3
PrimaryPercentage of Participants Experiencing an AE of Clinical Importance (ECI)

Adverse events of clinical importance, excluding overdoses include, but is not limited to, significant changes in alanine aminotransferase, aspartate aminotransferase, blood creatinine, glomerular filtration rate or hepatitis B reactivation.

Time frame:
Up to Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing an AE of Clinical Importance (ECI)
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Experiencing an AE of Clinical Importance (ECI)1.32.11.63.600
PrimaryPercentage of Participants Experiencing a Serious Adverse Event (SAE)

A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose.

Time frame:
Up to Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing a Serious Adverse Event (SAE)
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Experiencing a Serious Adverse Event (SAE)3.82.11.63.600
PrimaryPercentage of Participants Experiencing a Drug-related AE

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE is determined by the investigator to be related to the use of the drug.

Time frame:
Up to Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing a Drug-related AE
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Experiencing a Drug-related AE37.227.736.128.650.022.7
PrimaryPercentage of Participants Experiencing a Drug-related SAE

A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose. A drug-related SAE is determined by the investigator to be related to the use of the drug.

Time frame:
Up to Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing a Drug-related SAE
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Experiencing a Drug-related SAE000000
PrimaryPercentage of Participants Discontinuing Study Therapy Due to an AE

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing Study Therapy Due to an AE
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants Discontinuing Study Therapy Due to an AE1.32.11.61.804.5
SecondaryPercentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)

Plasma levels of HCV RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR24 is the absence of detectable RNA of the hepatitis C virus (\<LLOQ of 15 IU/mL), for at least 24 weeks after completing treatment.

Time frame:
24 weeks after completing study therapy (Week 36)
Reported as:
Number · Percentage of participants
Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)89.7 (80.8 to 95.5)85.1 (71.7 to 93.8)72.1 (59.2 to 82.9)96.4 (87.7 to 99.6)100.0 (81.5 to 100.0)81.8 (59.7 to 94.8)
SecondaryPercentage of Participants With Virologic Failure

Virologic failure is the detection of HCV RNA among participants who do not discontinue study for non-treatment-related reasons, either due to on-treatment failure defined as either non-response where HCV RNA is detected at end of treatment without HCV RNA \<LLOQ having been achieved while on treatment; rebound defined as \>1 log10 IU/mL increase in HCV RNA from nadir while on treatment and confirmed from a separate blood draw within 2 weeks; or virologic breakthrough which is confirmed HCV RNA ≥LLOQ (target detected, quantifiable \[TD(q)\]) after being \<LLOQ previously while on treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks; or relapse post-treatment. where there is a confirmed HCV RNA ≥LLOQ \[TD(q)\] following end of all study therapy, after becoming undetectable (target not detected \[TND\]) at end of treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks.

Time frame:
Up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Failure
Percentage of participantsHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Percentage of Participants With Virologic Failure3.82.123.00013.6

Adverse events

Collected over Up to Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HCV GT10/78 (0%)3/78 (3.8%)28/78 (35.9%)
HCV GT20/47 (0%)1/47 (2.1%)20/47 (42.6%)
HCV GT30/61 (0%)1/61 (1.6%)30/61 (49.2%)
HCV GT40/56 (0%)2/56 (3.6%)22/56 (39.3%)
HCV GT50/18 (0%)0/18 (0%)14/18 (77.8%)
HCV GT60/22 (0%)0/22 (0%)10/22 (45.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
Ovarian cystReproductive system and breast disorders0/781/470/610/560/180/22
DiarrhoeaGastrointestinal disorders0/780/470/611/560/180/22
Abscess limbInfections and infestations0/780/470/611/560/180/22
FallInjury, poisoning and procedural complications0/780/471/610/560/180/22
Ammonia increasedInvestigations0/780/471/610/560/180/22
Blood creatinine increasedInvestigations0/780/471/610/560/180/22
Glomerular filtration rate decreasedInvestigations0/780/471/610/560/180/22
RhabdomyolysisMusculoskeletal and connective tissue disorders0/780/471/610/560/180/22
Acute kidney injuryRenal and urinary disorders0/780/471/610/560/180/22
Acute coronary syndromeCardiac disorders1/780/470/610/560/180/22
Most frequent other events
Showing 10 of 36
Most frequent other events
EventHCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6
FatigueGeneral disorders14/785/475/614/560/181/22
Upper respiratory tract infectionInfections and infestations2/783/472/612/563/181/22
Blood creatine phosphokinase increasedInvestigations0/780/470/611/563/180/22
HeadacheNervous system disorders7/785/4710/618/562/181/22
Abdominal painGastrointestinal disorders1/781/471/612/562/181/22
DiarrhoeaGastrointestinal disorders3/782/472/613/562/181/22
ArthralgiaMusculoskeletal and connective tissue disorders3/780/471/612/562/180/22
Muscle spasmsMusculoskeletal and connective tissue disorders1/780/471/610/562/180/22
AstheniaGeneral disorders5/781/476/610/560/180/22
ConstipationGastrointestinal disorders2/781/471/611/560/182/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6Total
Mean47.9 ± 12.652.7 ± 11.948.4 ± 10.146.4 ± 13.057.4 ± 12.453.3 ± 11.049.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)HCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6Total
Female35242723116126
Male43233433716156
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HCV GT1HCV GT2HCV GT3HCV GT4HCV GT5HCV GT6Total
American Indian or Alaska Native0000000
Asian222012229
Native Hawaiian or Other Pacific Islander2101004
Black or African American40189022
White6944574740221
More than one race1010406
Unknown or Not Reported0000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11. PubMed 31108015 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Dec 2017, 13 months.

Results were first posted in Dec 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 6, 2016
StartActual
Nov 16, 2016
Primary completionActual
Dec 22, 2017
CompletionActual
Mar 5, 2018
Results first posted
Dec 26, 2018
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02956629
Responsible party
Sponsor
First posted
Nov 6, 2016
Start date
Nov 16, 2016
Primary completion
Dec 22, 2017
Completion
Mar 5, 2018
Results posted
Dec 26, 2018
Last update
Feb 2, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Uprifosbuvir · Ruzasvir

Start the discussion